This article is more than 5 years old. Information may no longer be current.
Canadian Bio Med Systems and Ocular Therapeutics acquire licensing rights to new drugs
Click Here to Manage Email Alerts
NEW YORK, MONTREAL and SAN DIEGO — Canadian Bio Med Systems and Ocular Therapeutics have acquired the licensing rights to two new drugs, the companies announced in a joint press release.
Daniel Stamer, PhD, and Ronald Heimark, PhD, are developing a drug for treating glaucoma at the University of Arizona, while Eugene Levin, PhD, is developing a new drug for treating age-related macular degeneration at Torrey Pines in San Diego, the release said.
Richard H. Keates, MD, chairman of Ocular Therapeutics, said the agreement with Canadian Bio Med Systems will allow the development of two important drugs in sizable markets.
Additional joint research is expected to begin in Canada under Dr. George Tsoukas of McGill University, according to the release.